Compare GSK plc (GSK) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Prospect Capital Corporation — how do they compare? GSK plc trades at $52.69 (market cap $101.34B), while Prospect Capital Corporation trades at $2.32 (market cap $1.14B). The key difference: GSK plc is far larger — about 88.9× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (22.03%). Which is the better fit depends on your goals.
| GSK | PSEC | |
|---|---|---|
Market Cap | $101.34B | $1.14B |
Sector | Health | Financials |
52-Week High | $61.18 | $3.47 |
52-Week Low | $36.20 | $2.15 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | 22.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
PSEC trades at $2.295, up 1.1% today, with a neutral technical signal and bearish moving averages. The stock shows a low P/B of 0.39 but negative revenue and net income in 2025. Recent earnings beats and consistent dividends highlight income potential, though financial performance remains volatile with a -495.94% net income margin. News includes a new investment in ShipOffers and the sale of Valley Electric.
Outlook is mixed: deep discount to NAV and high yield appeal to income seekers, but persistent financial deterioration and analyst skepticism pose risks. Upside depends on portfolio stability and NAV recovery, while downside risks include further dividend cuts and economic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
